On April 30, 2020 Notable, which is redefining cancer treatment with its scientific technology platform to rapidly advance drug development, reported a partnership with the MDS Foundation (Press release, Notable Labs, APR 30, 2020, View Source [SID1234556829]). MDS Foundation (MDSF) provides insight and information to families on upcoming clinical trials for myelodysplastic syndrome (MDS).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As part of the partnership, Notable is providing a grant to support MDSF’s critical education and advocacy efforts on behalf of MDS patients and their support network. Notable and MDSF will work closely together to engage physicians, biopharmaceutical companies, health authorities, and clinical trial organizations to collaborate on novel clinical trial designs. The goal of this effort is to match patients to effective drug therapies, and get those therapies approved faster for the benefit of all MDS patients.
The MDS Foundation is a non-profit organization dedicated to providing an ongoing exchange of information about MDS with patients and families. For clinical trials, the organization acts as an important conduit providing information, and translating technical jargon and medical terms and procedures for patients to better understand what each trial is about and what their participation will involve.
This partnership marks the MDS Foundation’s first time working with a scientific technology platform like Notable.
"Notable has breakthrough technology for accelerating drug development and precision medicine, matching patients with effective therapies," said Tracey Iraca, Executive Director of the MDS Foundation. "We are excited to work closely with Notable to continue to learn more about what its platform will mean for MDS research and help translate important information about MDS developments and trials to our community."
About the Collaboration
Educational patient-facing information highlighting key details about the trials in easy to understand descriptions will be communicated in various formats including social media, email, print, video and on the MDS Foundation’s website.
Furthermore, the MDS Foundation will also help connect the Notable team with MDS research through its Centers of Excellence network on available clinical trials, new research and treatment options.
"The MDS Foundation is paramount for communicating and educating the MDS community about groundbreaking research and treatments in this field," said Laurie Heilmann, CEO of Notable. "The combination of our scientific technology platform and the MDS Foundation’s charter will help advance functional precision medicine while educating patients and families about the latest clinical trials available."
Notable’s automated technology platform is built to help predict patient responses to cancer treatment therapies. As a precision oncology company, Notable matches patients with effective therapies and accelerates the drug development process for novel therapeutics. The company is developing the testing capability that will help physicians make better-informed decisions about which treatments and clinical trials might be most beneficial for their patients. A feasibility study conducted at the Stanford University School of Medicine demonstrated that Notable achieved an 84 percent overall accuracy rate in retrospectively predicting patient therapeutic responses. The most recent data from this collaboration was presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in December of 2019.